BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Retains Pharmaceutical Branding Agency to Oversee Lead Drug Candidate Naming Process
Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) this morning announced that it has retained the services of leading pharmaceutical branding agency, Addison Whitney, representing the next step toward commercialization of its lead drug candidate. Utilizing its 28-year history, Addison Whitney will oversee the proprietary and non-proprietary drug naming process for the company’s drug candidate for non-small cell lung cancer, presently known as Oncoprex(TM) immunogene therapy. “Retaining Addison Whitney is an important step in bringing our drug candidate to market,” Genprex Chairman and CEO Rodney Varner stated in the news release. “Obtaining regulatory approval of proprietary and non-proprietary drug names is a…